Peak Bio, a clinical-stage biopharmaceutical company, went public via a SPAC merger with Ignyte Acquisition, a blank cheque company, in a $378m deal. “We believe that Peak Bio is now well positioned to succeed in the public markets and look forward to updating the entire investment community on our progress in our differentiated approach in both oncology and rare inflammatory diseases,” Hoyoung Huh, Peak Bio Chairman and Founder.